Arbutus Biopharma (ABUS) Free Cash Flow (2013 - 2026)

Arbutus Biopharma has disclosed Free Cash Flow across 14 years of filings, most recently posting -$8.1 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$8.1 million, up 39.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.4 million (up 41.8% YoY), and the FY2025 annual result was -$39.6 million, up 39.05% from the prior year.
• Free Cash Flow came in at -$8.1 million for Q1 2026 at Arbutus Biopharma, down from -$4.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $20.5 million in Q1 2022 to a low of -$27.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$17.1 million (2022), against an average of -$13.9 million.
• Across the five-year window, Free Cash Flow soared 214.26% in 2022 and tumbled 233.46% in 2023, its largest moves.
• Arbutus Biopharma's Free Cash Flow stood at -$17.1 million in 2022, then decreased by 0.98% to -$17.3 million in 2023, then jumped by 39.85% to -$10.4 million in 2024, then soared by 55.0% to -$4.7 million in 2025, then slumped by 73.29% to -$8.1 million in 2026.
• The last three Free Cash Flow figures came in at -$8.1 million (Q1 2026), -$4.7 million (Q4 2025), and -$5.8 million (Q3 2025), per Business Quant data.